Maistop Completes Pre-A Round Financing to Advance Medical Radionuclide Industrialization via Electron Accelerator Method
August 12 news, Xi'an Maistop Technology Co., Ltd. recently completed its Pre-A round of financing, with investors including the Central Enterprise Strategic Emerging Fund and Guoxin Venture Capital Fund, both under China Reform Holdings Corporation. The proceeds from this round will primarily be used for site construction, equipment procurement, technology R&D, and daily operations. Founded in 2019, Maistop is a technology enterprise engaged in the R&D and production of medical radionuclides as well as nuclear medicine technical services. The company focuses on the preparation of medical radionuclides via the electron accelerator photonuclear reaction method, with core products including Actinium-225, Lead-212, Copper-67, and Molybdenum-99. Among these, Actinium-225 is a scarce radionuclide of significant interest in alpha-emitting nuclide targeted therapy, with relatively strong global clinical demand...
2026-08-13
